<DOC>
	<DOC>NCT00916617</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will receive active treatment (bapineuzumab) and no subjects will receive placebo.</brief_summary>
	<brief_title>Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable Alzheimer disease Completed preceding doubleblind study (3133L12203 US) MMSE score &gt; 9. Significant brain MRI abnormalities Clinically important psychiatric symptoms History of stroke</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>open-label</keyword>
	<keyword>safety</keyword>
	<keyword>antibody</keyword>
</DOC>